The present invention refers to a cell suspension comprising at least 90% of CD45RA− memory T cells, characterized in that the memory T cells are derived from blood of convalescent patients recovered from an infection with a respiratory pathogen and have specific lymphocyte antiviral reactivity against its antigens, for use in the treatment of immunocompromised patients suffering from lymphopenia.
1. Cell suspension comprising at least 90% of CD45RA- memory T cells, characterized in that the memory T cells are derived from blood of convalescent patients recovered from an infection with Coronavirus and have specific lymphocyte antiviral reactivity against Coronavirus antigens, for use in the treatment of immunocompromised patients suffering from lymphopenia. 2. Cell suspension for use, according to claim 1, characterized in that the memory T cells are derived from blood of convalescent patients recovered from an infection with SARS-CoV-2 and have specific lymphocyte antiviral reactivity against SARS-CoV-2 antigens. 3. Cell suspension for use, according to any of the previous claims, wherein at least 75% of the CD45RA- cells are CD3+ cells, wherein at least 70% of the CD45RA- CD3+ cells are CD4+ and wherein at least 10% of the CD45RA- CD3+ cells are CD8+. 4. Cell suspension for use, according to any of the previous claims, wherein at least 60% of the CD45RA- CD4+ cells are CD27+, wherein at least 5% of the CD45RA- CD4+ cells are CD27- and wherein at least 5% of the CD45RA- CD4+ cells are CD25+. 5. Cell suspension for use, according to any of the previous claims, wherein at least 50% of the CD45RA- CD8+ cells are CD27+ and wherein at least 10% of the CD45RA- CD8+ cells are CD27-. 6. Cell suspension for use, according to any of the previous claims, wherein at least 10% of the CD3+ cells are HLADR+, wherein at least 0.5% of the CD3+ cells are CD69<high+> and wherein at least 10% of the CD3+ cells are CD25+. 7. Cell suspension for use, according to any of the previous claims, wherein at least 5% of the CD4+ cells are HLADR+, wherein at least 0.2% of the CD4+ cells are CD69+, wherein at least 20% of the CD4+ cells are CD25+. 8. Cell suspension for use, according to any of the previous claims, wherein at least 5% of the CD8+ cells are HLADR+, wherein at least 0.15% of the CD8<high+> cells are CD69+, and wherein at least 4% of the CD8+ cells are CD25+. 9. Cell suspension for use, according to any of the previous claims, wherein less than 5% of the CD3+ cell are NKG2A+, wherein less than 1 % of the CD3+ cells are PD1+, wherein less than 0.1% of the CD4+ cells are NKG2A+, wherein less than 5% of the CD4+ cells are PD1+, wherein less than 20% of the CD8+ cells are NKG2A+ and wherein less than 5% of the CD8+ cells are PD1+. 10. Cell suspension for use, according to any of the previous claims, wherein at least 60% of the CD3+ cells are CCR7+, wherein at least 1% of the CD3+ cells are CD103+, wherein at least 50% of the CD4+ cells are CCR7+, wherein at least 0.5% of the CD4+ cells are CD103+, wherein at least 30% of the CD8+ cells are CCR7+ and wherein at least 2% of the CD8+ cells are CD103+. 11. Cell suspension for use, according to any of the previous claims, wherein the expression of the activation markers CD69, CD25, HLADR and/or CD103 is characterized by a fold change of at least 1.5 when compared with the expression measured in the basal cell population and consequently show an improvement in activation markers and migration capacity to the respiratory track. 12. Cell suspension for use, according to any of the previous claims, as adoptive third-party off-the-shelf treatment in patients suffering from lymphopenia caused by a viral infection, preferably caused by Coronavirus. 13. Cell suspension for use, according to any of the previous claims, in the treatment of immunocompromised patients suffering from lymphopenia caused by a viral infection, preferably caused by SARS-CoV-2. 14. Cell suspension for use, according to any of the previous claims, wherein the cell suspension is administered either intravenously, by nebulization or locally in the oral, nasal or ocular mucosae. 15. Pharmaceutical composition comprising the cell suspension of any of the claims 3 to 14 and, optionally, pharmaceutically acceptable excipients and/or carriers.